Peter Ruf

1.3k total citations
30 papers, 998 citations indexed

About

Peter Ruf is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Peter Ruf has authored 30 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Radiology, Nuclear Medicine and Imaging, 19 papers in Oncology and 15 papers in Immunology. Recurrent topics in Peter Ruf's work include Monoclonal and Polyclonal Antibodies Research (22 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (15 papers). Peter Ruf is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (15 papers). Peter Ruf collaborates with scholars based in Germany, Romania and United Kingdom. Peter Ruf's co-authors include Horst Lindhofer, Michael Jäger, Juergen Heß, A. Schoberth, Jürgen Hess, Ralph Mocikat, Nina Eißler, Marc C. Winslet, Matthias Plöscher and Pauline Wimberger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Peter Ruf

30 papers receiving 951 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ruf Germany 15 609 513 369 323 96 30 998
Kathrin Schwager Switzerland 14 482 0.8× 487 0.9× 375 1.0× 301 0.9× 96 1.0× 17 1.0k
Mildred Felder United States 17 421 0.7× 109 0.2× 467 1.3× 445 1.4× 93 1.0× 39 1.1k
Irene Venturo United States 15 525 0.9× 243 0.5× 288 0.8× 336 1.0× 57 0.6× 38 1.0k
E. Kutarska Poland 12 440 0.7× 200 0.4× 211 0.6× 274 0.8× 178 1.9× 17 939
Mischa Houtkamp Netherlands 10 376 0.6× 274 0.5× 294 0.8× 207 0.6× 51 0.5× 16 782
M. I. Colnaghi Italy 15 585 1.0× 402 0.8× 273 0.7× 487 1.5× 51 0.5× 26 1.1k
G.L. Buraggi Italy 15 310 0.5× 583 1.1× 106 0.3× 205 0.6× 46 0.5× 43 811
Debora Pezzuolo Italy 6 566 0.9× 487 0.9× 344 0.9× 312 1.0× 35 0.4× 13 950
Joshua Z. Drago United States 9 742 1.2× 454 0.9× 95 0.3× 356 1.1× 44 0.5× 28 1.1k
Sylvie Rusakiewicz France 22 800 1.3× 98 0.2× 800 2.2× 322 1.0× 70 0.7× 44 1.4k

Countries citing papers authored by Peter Ruf

Since Specialization
Citations

This map shows the geographic impact of Peter Ruf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ruf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ruf more than expected).

Fields of papers citing papers by Peter Ruf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ruf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ruf. The network helps show where Peter Ruf may publish in the future.

Co-authorship network of co-authors of Peter Ruf

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ruf. A scholar is included among the top collaborators of Peter Ruf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ruf. Peter Ruf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Antoniewicz, Artur A., Frederik Wessels, M. Lenhart, et al.. (2024). 2010P Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study. Annals of Oncology. 35. S1160–S1160. 3 indexed citations
2.
Klaus, Anika, Peter Ruf, Horst Lindhofer, et al.. (2023). Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model. Frontiers in Immunology. 13. 1023206–1023206. 7 indexed citations
3.
4.
Winter, Andreas, Kai Zacharowski, Patrick Meybohm, et al.. (2021). Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study. BMC Anesthesiology. 21(1). 261–261. 4 indexed citations
5.
Atmaca, Akin, Claudia Pauligk, K. Steinmetz, et al.. (2016). A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 16(1). 420–420. 54 indexed citations
6.
7.
Ruf, Peter, Nina Eißler, Frauke Neff, et al.. (2015). Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery. Molecular Cancer Therapeutics. 14(8). 1877–1883. 13 indexed citations
8.
Heubner, Martin, Pauline Wimberger, Sabine Kasimir‐Bauer, et al.. (2015). Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects. Archives of Gynecology and Obstetrics. 292(6). 1367–1372. 1 indexed citations
9.
10.
Ruf, Peter, Beatrix Schäfer, Nina Eißler, et al.. (2012). Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model. Journal of Translational Medicine. 10(1). 219–219. 24 indexed citations
11.
Ruf, Peter, Michael Kluge, Michael Jäger, et al.. (2010). Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. British Journal of Clinical Pharmacology. 69(6). 617–625. 65 indexed citations
12.
Chelius, Dirk, Peter Ruf, Patrick Gruber, et al.. (2010). Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs. 2(3). 309–319. 112 indexed citations
13.
Kunzmann, Volker, et al.. (2010). Catumaxomab observational study to investigate efficacy and safety profile in clinical practice.. Journal of Clinical Oncology. 28(15_suppl). TPS156–TPS156. 1 indexed citations
14.
Jäger, Michael, A. Schoberth, Peter Ruf, Jürgen Hess, & Horst Lindhofer. (2009). The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2. Cancer Research. 69(10). 4270–4276. 79 indexed citations
15.
Morecki, Shoshana, et al.. (2008). Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Experimental Hematology. 36(8). 997–1003. 32 indexed citations
16.
JAGER, MJ, et al.. (2008). Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab. Journal of Clinical Oncology. 26(15_suppl). 3071–3071. 4 indexed citations
17.
18.
Ruf, Peter, et al.. (2007). EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. British Journal of Cancer. 96(7). 1013–1019. 76 indexed citations
19.
Kiewe, Philipp, Alexander Schmittel, Peter Ruf, et al.. (2006). Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma. Annals of Oncology. 17(12). 1830–1834. 5 indexed citations
20.
Ruf, Peter, et al.. (2003). Two new trifunctional antibodies for the therapy of human malignant melanoma. International Journal of Cancer. 108(5). 725–732. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathrin Schwager Breakdown of academic impact, for papers by Mildred Felder Breakdown of academic impact, for papers by Irene Venturo Breakdown of academic impact, for papers by E. Kutarska Breakdown of academic impact, for papers by Mischa Houtkamp Breakdown of academic impact, for papers by M. I. Colnaghi Breakdown of academic impact, for papers by G.L. Buraggi Breakdown of academic impact, for papers by Debora Pezzuolo Breakdown of academic impact, for papers by Joshua Z. Drago Breakdown of academic impact, for papers by Sylvie Rusakiewicz
Rankless by CCL
2026